Genmab A/S (GNMSF)

272,81 -1,41 (-0,51 %) À la clôture : 03:37PM EDT

Genmab A/S

Carl Jacobsens Vej 30
Valby
Copenhagen 2500
Denmark
45 70 20 27 28
https://www.genmab.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 2 204

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Jan G.J. van de Winkel Ph.D.	Co-Founder, President & CEO	2,86M	S.O.	1961
Mr. Anthony Pagano	Executive VP & CFO	1,02M	S.O.	1978
Ms. Birgitte Stephensen M.Sc.	Executive VP & Chief Legal Officer	629,18k	S.O.	1961
Dr. Martine J. van Vugt Ph.D.	Executive VP & Chief Strategy Officer	686,38k	S.O.	1971
Mr. Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	114,4k	S.O.	1976
Dr. Tahamtan Ahmadi	Executive VP, Chief Medical Officer & Head of Experimental Medicines	1,1M	S.O.	1973
Dr. Mijke Zachariasse Ph.D.	Senior Director, Head of Antibody Research Materials & Non-Independent Director	157,3k	S.O.	1974
Mr. Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	114,4k	S.O.	1975
Mr. Anthony Mancini	Executive VP & COO	1,09M	S.O.	1971
Mr. Andrew Carlsen	Senior Director, VP & Head of Investor Relations	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Genmab A/S en date du 29 avril 2024 est 4. Les scores principaux sont Audit : 2; Société : 1; Droits des actionnaires : 1; Compensation : 8.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.